A Phase 2/3 interventional study of Ublituximab and Umbralisib in Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma, sponsored by TG Therapeutics, Inc.. Terminated at 50 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-04-19.
Sponsored by TG Therapeutics, Inc. · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies testing ublituximab in Leukemia, Lymphocytic, Chronic, B-Cell — none open to participants now, 1 under way, none of them phase 3. ublituximab · Leukemia, Lymphocytic, Chronic, B-Cell.
Among the 13 studies testing ublituximab in Leukemia, Lymphocytic, Chronic, B-Cell, this one is the 2nd largest by enrollment, is one of 2 that started in 2019, is the only one in phase 2/3, and was the 10th registered.
2,036 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 236 are open to participants now.
Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →None of the 13 studies testing ublituximab in Leukemia, Lymphocytic, Chronic, B-Cell is open now. The open studies under Leukemia, Lymphocytic, Chronic, B-Cell, anywhere →
ublituximab: first FDA approval 2022 (BRIUMVI), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →
Of the 187 Leukemia, Lymphocytic, Chronic, B-Cell studies recruiting now, 150 (80%) set no upper age limit and 15 (8%) stop at 75 or younger; 17 take children under 18; 12 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 8 · Phase 3 3
First in 2008; this study’s year is marked. 2 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 277 is above the median of 39 across 1,603 interventional studies indexed under Leukemia, Lymphocytic, Chronic, B-Cell.
Median enrollment 51 across the 13 interventional studies. Of the 12 that completed or were terminated, 6 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 13 have an industry lead sponsor. The 4 most frequent:
TG Therapeutics, Inc. is the lead sponsor of 40 studies on the registry; 9 are open to participants now.
Of its 16 completed or terminated interventional studies of FDA-regulated products, 9 (56%) have results posted.
18 studies in Leukemia, Lymphocytic, Chronic, B-Cell by TG Therapeutics, Inc.: none open now, none under way, none of them phase 3. Of 18 finished, 7 (39%) have results posted.
Among the 18 studies in Leukemia, Lymphocytic, Chronic, B-Cell by TG Therapeutics, Inc., this one is the 3rd largest by enrollment, is one of 3 that started in 2019, is one of 2 in phase 2/3, and was the 16th registered.
TG Therapeutics, Inc.’s Leukemia, Lymphocytic, Chronic, B-Cell studies by the year they started, since 2012.
None of the studies under way reaches primary completion within a year.
Among the 13 studies testing ublituximab in Leukemia, Lymphocytic, Chronic, B-Cell, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among TG Therapeutics, Inc.’s 18 in Leukemia, Lymphocytic, Chronic, B-Cell:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
ULTRA-V: Study to Assess the Efficacy and Safety of Ublituximab in Combination with Umbralisib and Venetoclax (U2-V) Compared to Ublituximab and Umbralisib (U2) in Subjects with Chronic Lymphocytic Leukemia (CLL)
This is an open-label, multicenter, Phase 2/3 study to evaluate the efficacy and safety of the combination of ublituximab + umbralisib + venetoclax (U2-V) compared to the combination of ublituximab + umbralisib (U2) in participants with either treatment naïve or previously treated CLL/ small lymphocytic lymphoma (SLL).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants were administered ublituximab, 150 milligrams (mg), intravenous (IV) infusion on Day 1, 750 mg on Day 2, 900 mg on Days 8 and 15 of Cycle 1, followed by 900 mg on Day 1 of Cycles 2-6; umbralisib, 800 mg, oral tablet, once daily (QD) through Cycles 1-24; venetoclax, oral tablet, QD, 20 mg on Days 1-7, 50 mg on Days 8-14, 100 mg on Days 15-21, 200 mg on Days 22-28 of Cycle 4, followed by 400 mg on Days 1-28 of Cycles 5-24. MRD positive participants were administered umbralisib, 800 mg, oral tablet, QD, on Days 1-28 from Cycle 25 onwards (1 Cycle = 28 days), until disease progression, unacceptable toxicity, or withdrawal from the study.
Drug: Ublituximab · Drug: Umbralisib · Drug: Venetoclax
Participants were administered ublituximab, 150 mg, IV infusion on Day 1, 750 mg on Day 2, 900 mg on Days 8 and 15 of Cycle 1, followed by 900 mg on Day 1 of Cycles 2-6, 9,12, and 15; umbralisib, 800 mg, oral tablet, QD through Cycles 1-15; venetoclax, oral tablet, QD, 20 mg on Days 1-7, 50 mg on Days 8-14, 100 mg on Days 15-21, 200 mg on Days 22-28 of Cycle 4, followed by 400 mg on Days 1-28 of Cycles 5-15 (1 Cycle = 28 days).
Drug: Ublituximab · Drug: Umbralisib · Drug: Venetoclax
Participants were administered ublituximab, 150 mg, IV infusion on Day 1, 750 mg on Day 2, 900 mg on Days 8 and 15 of Cycle 1, followed by 900 mg on Day 1 of Cycles 2-6, then every three cycles along with umbralisib, 800 mg, oral tablet, QD (1 Cycle = 28 days) from Cycle 1 until disease progression, unacceptable toxicity, or withdrawal from the study.
Drug: Ublituximab · Drug: Umbralisib
* recombinant chimeric anti-CD20 (cluster of differentiation 20) monoclonal antibody * administered as an IV infusion
Also known as: TG-1101
* inhibitor of phosphoinositide 3-kinase (PI3K) delta and casein kinase 1 epsilon (CK1e) * Tablet form
Also known as: TGR-1202, UKONIQ
* B-cell lymphoma 2 (BCL-2) inhibitor * Tablet form
Also known as: Venclexta®
Phase 2: Complete Response (CR) Rate as Per International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 2018 Criteria
CR rate=percent of participants who achieved CR or complete response with incomplete marrow recovery(CRi).CR=no evidence of new disease,absolute lymphocyte count(ALC) in peripheral blood\<4x10\^9 per liter(/L),regression of nodal masses to normal size \<1.5 centimeters(cm) in longest diameter(LD),normal spleen and liver size,no constitutional symptoms,cytological/pathological evaluation of bone marrow(BM) smear/biopsy must be at least normocellular for age without evidence for typical chronic lymphocytic leukemia(CLL)/small lymphocytic lymphoma(SLL) lymphocytes by morphological criteria,peripheral blood counts with absolute neutrophil count(ANC)≥1.5x10\^9/L or platelet≥100x10\^9/L or hemoglobin≥110 grams per liter(g/L) without red blood cell(RBC) transfusions,all without need for exogenous growth factors.CRi=all CR criteria but with persistent anemia,thrombocytopenia,or neutropenia or hypocellular BM that is related to prior/ongoing drug toxicity(and not to CLL/SLL).
Time frame: Up to 43.2 months
Phase 2: Overall Response Rate (ORR) Per iwCLL 2018 Criteria
ORR=percent of participants who achieve CR,CRi,partial response(PR) or PR with lymphocytosis(PR-L).CR=no evidence of new disease;ALC\<4x10\^9/L;regression of nodal masses to\<1.5cm LD;normal spleen,liver size;no constitutional symptoms;cytological/pathological evaluation of BM smear/biopsy must be at least normocellular for age;ANC≥1.5x10\^9/L,platelet≥100x10\^9/L,Hb≥110g/L.CRi=CR criteria but with persistent anemia,thrombocytopenia,or neutropenia/hypocellular BM related to prior/ongoing drug toxicity.PR=no evidence of new disease,meets≥2 criteria:≥50% decrease from baseline(BL) in ALC(or decrease to\<4x10\^9/L) or sum of products(SPD) of target nodal lesions or CLL/SLL marrow infiltrate/Blymphoid;no target,splenic,liver,or non-target disease with worsening that meets criteria for definitive progressive disease(PD);platelet\>100x10\^9/L or Hb≥110g/L or ≥50% increase from BL in each.PR-L=PR criteria but not had ≥50% decrease from BL in ALC/decrease to\<4x10\^9/L.
Time frame: Up to 43.2 months
Phase 3: Progression-Free Survival (PFS) Per iwCLL 2018 Criteria
PFS was assessed in participants treated with U2-V compared with U2. PFS was defined as the interval between randomization and the date of definitive PD (as confirmed by the IRC) or death due to any cause, whichever occurs first. Participants who had no event (progression or death) were censored at the day of their last adequate disease assessment. PD= appearance of new nodes \>1.5 cm in the LD, \>50% increase in greatest diameter, new or recurrent hepatomegaly or splenomegaly, new unequivocal extra-nodal lesion, new non-target disease, ≥50% increase from the nadir in the sum of products of diameters (SPD) of target lesions, ≥50% increase in the LD of an individual node or extra-nodal mass, splenic/hepatic enlargement of ≥50% from nadir, unequivocal increase in the size of non-target disease, transformation to a more aggressive histology, decrease in platelet count or Hgb, \>50% decrease from the highest on-study platelet count, \>20 g/L decrease from the highest on-study Hgb.
Time frame: Up to 43.2 months
Minimal Residual Disease (MRD) Negativity Rate
The MRD negativity rate was defined as the percentage of participants who achieved MRD negative status post-baseline, defined as a quantitative detection of less than one CLL/SLL cell in 10000 leukocytes by flow cytometry (MRD level, 10\^-4) in blood or bone marrow (BM). If a participant was determined to be MRD negative by peripheral blood, a bone marrow aspirate was obtained to assess MRD in the bone marrow. Participants who did not have an MRD assessment at any post-baseline visits were considered non-responders and were included in the denominator when calculating MRD negativity rate.
Time frame: Up to 43.2 months
Number of Participants Experiencing at Least One Treatment-Emergent Adverse Event (TEAE)
An adverse event (AE) is any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product. An AE does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporarily associated with the use of a medicinal product, whether or not considered related to the medicinal product. TEAE is any AE that occur after first dosing of study medication and through the end of the study or through 30 days after the last dose of study treatment, or is considered treatment-related regardless of the start date of the event, or is present before first dosing of study medication but worsens in intensity or the investigator subsequently considers treatment-related.
Time frame: Up to 43.2 months
Phase 2: Time to Response (TTR) Per iwCLL 2018 Criteria
TTR was defined as the interval from enrollment to first documentation of CR, CRi, PR, or PR-L. TTR was analyzed via Kaplan-Meier method. CR=no evidence of new disease; ALC\<4x10\^9/L; regression of nodal masses to \<1.5cm LD; normal spleen ,liver size; no constitutional symptoms; cytological/pathological evaluation of BM smear/biopsy must be at least normocellular for age; ANC≥1.5x10\^9/L, platelet≥100x10\^9/L, Hb≥110g/L. CRi=CR criteria but with persistent anemia, thrombocytopenia, or neutropenia/hypocellular BM related to prior/ongoing drug toxicity.PR=no evidence of new disease,meets≥2 criteria:≥50% decrease from BL in ALC (or decrease to\<4x10\^9/L) or SPD of target nodal lesions or CLL/SLL marrow infiltrate/B-lymphoid; no target, splenic, liver, or non-target disease with worsening that meets criteria for definitive PD; platelet\>100x10\^9/L or Hb≥110g/L or ≥50% increase from BL in each.PR-L=PR criteria but not had ≥50% decrease from BL in ALC/decrease to\<4x10\^9/L.
Time frame: Up to 43.2 months
Phase 2: Duration of Response (DOR) Per iwCLL 2018 Criteria
DOR=interval from 1st documentation of CR,CRi,PR or PR-L to earlier of 1st documentation of definitive PD or death from any cause.CR=no evidence of new disease;ALC\<4x10\^9/L;regression of nodal masses to\<1.5cm LD;normal spleen,liver size;no constitutional symptoms;cytological/pathological evaluation of BM smear/biopsy must be at least normocellular for age;ANC≥1.5x10\^9/L,platelet≥100x10\^9/L,Hb≥110g/L.CRi=CR criteria but with persistent anemia,thrombocytopenia,neutropenia/hypocellular BM related to prior/ongoing drug toxicity.PR=no evidence of new disease,meets≥2 criteria:≥50% decrease from BL in ALC(or decrease to\<4x10\^9/L) or SPD of target nodal lesions or CLL/SLL marrow infiltrate/Blymphoid;no target,splenic,liver,or non-target disease with worsening that meets criteria for definitive PD;platelet\>100x10\^9/L or Hb≥110g/L or ≥50% increase from BL in each.PR-L=PR criteria;not≥50% decrease from BL in ALC/decrease to\<4x10\^9/L.PD=evidence of new disease per protocol-specififed criteria.
Time frame: Up to 43.2 months
Phase 3: CR Rate as Assessed by an Independent Review Committee (IRC) Per iwCLL 2018 Criteria
CR rate=percent of participants who achieved CR or CRi. CR=no evidence of new disease; ALC\<4x10\^9/L; regression of nodal masses to \<1.5 cm LD; normal spleen, liver size; no constitutional symptoms; cytological/pathological evaluation of BM smear/biopsy must be at least normocellular for age; ANC ≥1.5x10\^9/L, platelet ≥100x10\^9/L, Hb ≥110g/L. CRi=CR criteria but with persistent anemia,thrombocytopenia,or neutropenia/hypocellular BM related to prior/ongoing drug toxicity. CR assessment was subject to independent confirmation by the IRC in participants enrolled to the Phase 3 stage of the study.
Time frame: Up to 43.2 months
Phase 3: ORR as Assessed by IRC Per iwCLL 2018 Criteria
ORR=percent of participants who achieve CR, CRi, PR or PR-L.CR=no evidence of new disease; ALC\<4x10\^9/L; regression of nodal masses to\<1.5cm LD; normal spleen and liver size; no constitutional symptoms; cytological/pathological evaluation of BM smear/biopsy must be at least normocellular for age; ANC≥1.5x10\^9/L, platelet≥100x10\^9/L, Hb≥110g/L. CRi=CR criteria but with persistent anemia, thrombocytopenia, or neutropenia/hypocellular BM related to prior/ongoing drug toxicity.PR=no evidence of new disease,meets≥2 criteria:≥50% decrease from baseline (BL) in ALC (or decrease to\<4x10\^9/L) or SPD of target nodal lesions or CLL/SLL marrow infiltrate/B-lymphoid; no target, splenic, liver, or non-target disease with worsening that meets criteria for definitive PD; platelet\>100x10\^9/L or Hb≥110g/L or ≥50% increase from BL in each.PR-L=PR criteria but not had ≥50% decrease from BL in ALC/decrease to\<4x10\^9/L.
Time frame: Up to 43.2 months
Phase 3: Overall Survival (OS)
Overall Survival (OS) was defined as the interval from randomization to death from any cause. OS data was censored at the last documented date that the participant was confirmed alive for participants who withdrew consent or were lost to follow-up prior to the end of the study, and for participants whose vital status in the study could not be determined.
Time frame: Up to 43.2 months
A total of 277 participants were enrolled at investigative sites in the United States from 16 May 2019 to 20 December 2022.
| Milestone | Phase 2: Ublituximab + Umbralisib + Venetoclax (U2-V) | Phase 3: Ublituximab + Umbralisib + Venetoclax (U2-V) | Phase 3: Ublituximab + Umbralisib (U2) |
|---|---|---|---|
| Started | 165 | 56 | 56 |
| Intent-to-treat (itt) population | 149 | 56 | 56 |
| Completed | 11 | 0 | 0 |
| Not completed | 154 | 56 | 56 |
| Withdrew: Adverse event | 17 | 1 | 0 |
| Withdrew: Conditions requiring therapeutic intervention not permitted by the protocol | 1 | 0 | 0 |
| Withdrew: Death | 29 | 1 | 4 |
| Withdrew: Disease progression | 6 | 0 | 1 |
| Withdrew: Inability to comply with study requirements | 1 | 1 | 0 |
| Withdrew: Investigator decision | 18 | 1 | 0 |
| Withdrew: Minimal residual disease (mrd) negativity and tumor response | 14 | 0 | 0 |
| Withdrew: Sponsor discontinuation of the study | 24 | 49 | 43 |
| Withdrew: Started non-protocol anti-cancer therapy | 2 | 1 | 3 |
| Withdrew: Withdrawal of subject consent | 38 | 2 | 1 |
| Withdrew: Reason not specified | 4 | 0 | 4 |
CR rate=percent of participants who achieved CR or complete response with incomplete marrow recovery(CRi).CR=no evidence of new disease,absolute lymphocyte count(ALC) in peripheral blood\<4x10\^9 per liter(/L),regression of nodal masses to normal size \<1.5 centimeters(cm) in longest diameter(LD),normal spleen and liver size,no constitutional symptoms,cytological/pathological evaluation of bone marrow(BM) smear/biopsy must be at least normocellular for age without evidence for typical chronic lymphocytic leukemia(CLL)/small lymphocytic lymphoma(SLL) lymphocytes by morphological criteria,peripheral blood counts with absolute neutrophil count(ANC)≥1.5x10\^9/L or platelet≥100x10\^9/L or hemoglobin≥110 grams per liter(g/L) without red blood cell(RBC) transfusions,all without need for exogenous growth factors.CRi=all CR criteria but with persistent anemia,thrombocytopenia,or neutropenia or hypocellular BM that is related to prior/ongoing drug toxicity(and not to CLL/SLL).
| percentage of participants | Phase 2: Ublituximab + Umbralisib + Venetoclax (U2-V) |
|---|---|
| Phase 2: Complete Response (CR) Rate as Per International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 2018 Criteria | 33.6 |
ORR=percent of participants who achieve CR,CRi,partial response(PR) or PR with lymphocytosis(PR-L).CR=no evidence of new disease;ALC\<4x10\^9/L;regression of nodal masses to\<1.5cm LD;normal spleen,liver size;no constitutional symptoms;cytological/pathological evaluation of BM smear/biopsy must be at least normocellular for age;ANC≥1.5x10\^9/L,platelet≥100x10\^9/L,Hb≥110g/L.CRi=CR criteria but with persistent anemia,thrombocytopenia,or neutropenia/hypocellular BM related to prior/ongoing drug toxicity.PR=no evidence of new disease,meets≥2 criteria:≥50% decrease from baseline(BL) in ALC(or decrease to\<4x10\^9/L) or sum of products(SPD) of target nodal lesions or CLL/SLL marrow infiltrate/Blymphoid;no target,splenic,liver,or non-target disease with worsening that meets criteria for definitive progressive disease(PD);platelet\>100x10\^9/L or Hb≥110g/L or ≥50% increase from BL in each.PR-L=PR criteria but not had ≥50% decrease from BL in ALC/decrease to\<4x10\^9/L.
| percentage of participants | Phase 2: Ublituximab + Umbralisib + Venetoclax (U2-V) |
|---|---|
| Phase 2: Overall Response Rate (ORR) Per iwCLL 2018 Criteria | 93.3 |
PFS was assessed in participants treated with U2-V compared with U2. PFS was defined as the interval between randomization and the date of definitive PD (as confirmed by the IRC) or death due to any cause, whichever occurs first. Participants who had no event (progression or death) were censored at the day of their last adequate disease assessment. PD= appearance of new nodes \>1.5 cm in the LD, \>50% increase in greatest diameter, new or recurrent hepatomegaly or splenomegaly, new unequivocal extra-nodal lesion, new non-target disease, ≥50% increase from the nadir in the sum of products of diameters (SPD) of target lesions, ≥50% increase in the LD of an individual node or extra-nodal mass, splenic/hepatic enlargement of ≥50% from nadir, unequivocal increase in the size of non-target disease, transformation to a more aggressive histology, decrease in platelet count or Hgb, \>50% decrease from the highest on-study platelet count, \>20 g/L decrease from the highest on-study Hgb.
| months | Phase 3: Ublituximab + Umbralisib + Venetoclax (U2-V) | Phase 3: Ublituximab + Umbralisib (U2) |
|---|---|---|
| Phase 3: Progression-Free Survival (PFS) Per iwCLL 2018 Criteria | NA (0.0 to 15.7) | NA (0.0 to 13.1) |
The MRD negativity rate was defined as the percentage of participants who achieved MRD negative status post-baseline, defined as a quantitative detection of less than one CLL/SLL cell in 10000 leukocytes by flow cytometry (MRD level, 10\^-4) in blood or bone marrow (BM). If a participant was determined to be MRD negative by peripheral blood, a bone marrow aspirate was obtained to assess MRD in the bone marrow. Participants who did not have an MRD assessment at any post-baseline visits were considered non-responders and were included in the denominator when calculating MRD negativity rate.
| percentage of participants | Phase 2: Ublituximab + Umbralisib + Venetoclax (U2-V) | Phase 3: Ublituximab + Umbralisib + Venetoclax (U2-V) | Phase 3: Ublituximab + Umbralisib (U2) |
|---|---|---|---|
| Minimal Residual Disease (MRD) Negativity Rate | 94.0 (88.8 to 97.2) | 50.0 (36.3 to 63.7) | 19.6 (10.2 to 32.4) |
An adverse event (AE) is any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product. An AE does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporarily associated with the use of a medicinal product, whether or not considered related to the medicinal product. TEAE is any AE that occur after first dosing of study medication and through the end of the study or through 30 days after the last dose of study treatment, or is considered treatment-related regardless of the start date of the event, or is present before first dosing of study medication but worsens in intensity or the investigator subsequently considers treatment-related.
| Participants | Phase 2: Ublituximab + Umbralisib + Venetoclax (U2-V) | Phase 3: Ublituximab + Umbralisib + Venetoclax (U2-V) | Phase 3: Ublituximab + Umbralisib (U2) |
|---|---|---|---|
| Number of Participants Experiencing at Least One Treatment-Emergent Adverse Event (TEAE) | 165 | 56 | 51 |
TTR was defined as the interval from enrollment to first documentation of CR, CRi, PR, or PR-L. TTR was analyzed via Kaplan-Meier method. CR=no evidence of new disease; ALC\<4x10\^9/L; regression of nodal masses to \<1.5cm LD; normal spleen ,liver size; no constitutional symptoms; cytological/pathological evaluation of BM smear/biopsy must be at least normocellular for age; ANC≥1.5x10\^9/L, platelet≥100x10\^9/L, Hb≥110g/L. CRi=CR criteria but with persistent anemia, thrombocytopenia, or neutropenia/hypocellular BM related to prior/ongoing drug toxicity.PR=no evidence of new disease,meets≥2 criteria:≥50% decrease from BL in ALC (or decrease to\<4x10\^9/L) or SPD of target nodal lesions or CLL/SLL marrow infiltrate/B-lymphoid; no target, splenic, liver, or non-target disease with worsening that meets criteria for definitive PD; platelet\>100x10\^9/L or Hb≥110g/L or ≥50% increase from BL in each.PR-L=PR criteria but not had ≥50% decrease from BL in ALC/decrease to\<4x10\^9/L.
| months | Phase 2: Ublituximab + Umbralisib + Venetoclax (U2-V) |
|---|---|
| Phase 2: Time to Response (TTR) Per iwCLL 2018 Criteria | 2.6 (2.3 to 18.5) |
DOR=interval from 1st documentation of CR,CRi,PR or PR-L to earlier of 1st documentation of definitive PD or death from any cause.CR=no evidence of new disease;ALC\<4x10\^9/L;regression of nodal masses to\<1.5cm LD;normal spleen,liver size;no constitutional symptoms;cytological/pathological evaluation of BM smear/biopsy must be at least normocellular for age;ANC≥1.5x10\^9/L,platelet≥100x10\^9/L,Hb≥110g/L.CRi=CR criteria but with persistent anemia,thrombocytopenia,neutropenia/hypocellular BM related to prior/ongoing drug toxicity.PR=no evidence of new disease,meets≥2 criteria:≥50% decrease from BL in ALC(or decrease to\<4x10\^9/L) or SPD of target nodal lesions or CLL/SLL marrow infiltrate/Blymphoid;no target,splenic,liver,or non-target disease with worsening that meets criteria for definitive PD;platelet\>100x10\^9/L or Hb≥110g/L or ≥50% increase from BL in each.PR-L=PR criteria;not≥50% decrease from BL in ALC/decrease to\<4x10\^9/L.PD=evidence of new disease per protocol-specififed criteria.
| months | Phase 2: Ublituximab + Umbralisib + Venetoclax (U2-V) |
|---|---|
| Phase 2: Duration of Response (DOR) Per iwCLL 2018 Criteria | 21.1 (0.0 to 24.8) |
CR rate=percent of participants who achieved CR or CRi. CR=no evidence of new disease; ALC\<4x10\^9/L; regression of nodal masses to \<1.5 cm LD; normal spleen, liver size; no constitutional symptoms; cytological/pathological evaluation of BM smear/biopsy must be at least normocellular for age; ANC ≥1.5x10\^9/L, platelet ≥100x10\^9/L, Hb ≥110g/L. CRi=CR criteria but with persistent anemia,thrombocytopenia,or neutropenia/hypocellular BM related to prior/ongoing drug toxicity. CR assessment was subject to independent confirmation by the IRC in participants enrolled to the Phase 3 stage of the study.
| percentage of participants | Phase 3: Ublituximab + Umbralisib + Venetoclax (U2-V) | Phase 3: Ublituximab + Umbralisib (U2) |
|---|---|---|
| Phase 3: CR Rate as Assessed by an Independent Review Committee (IRC) Per iwCLL 2018 Criteria | 17.9 | 8.9 |
ORR=percent of participants who achieve CR, CRi, PR or PR-L.CR=no evidence of new disease; ALC\<4x10\^9/L; regression of nodal masses to\<1.5cm LD; normal spleen and liver size; no constitutional symptoms; cytological/pathological evaluation of BM smear/biopsy must be at least normocellular for age; ANC≥1.5x10\^9/L, platelet≥100x10\^9/L, Hb≥110g/L. CRi=CR criteria but with persistent anemia, thrombocytopenia, or neutropenia/hypocellular BM related to prior/ongoing drug toxicity.PR=no evidence of new disease,meets≥2 criteria:≥50% decrease from baseline (BL) in ALC (or decrease to\<4x10\^9/L) or SPD of target nodal lesions or CLL/SLL marrow infiltrate/B-lymphoid; no target, splenic, liver, or non-target disease with worsening that meets criteria for definitive PD; platelet\>100x10\^9/L or Hb≥110g/L or ≥50% increase from BL in each.PR-L=PR criteria but not had ≥50% decrease from BL in ALC/decrease to\<4x10\^9/L.
| percentage of participants | Phase 3: Ublituximab + Umbralisib + Venetoclax (U2-V) | Phase 3: Ublituximab + Umbralisib (U2) |
|---|---|---|
| Phase 3: ORR as Assessed by IRC Per iwCLL 2018 Criteria | 71.4 | 62.5 |
Overall Survival (OS) was defined as the interval from randomization to death from any cause. OS data was censored at the last documented date that the participant was confirmed alive for participants who withdrew consent or were lost to follow-up prior to the end of the study, and for participants whose vital status in the study could not be determined.
| months | Phase 3: Ublituximab + Umbralisib + Venetoclax (U2-V) | Phase 3: Ublituximab + Umbralisib (U2) |
|---|---|---|
| Phase 3: Overall Survival (OS) | NA (0.5 to 16.6) | NA (0.0 to 16.2) |
Collected over Up to 43.2 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Phase 2: Ublituximab + Umbralisib + Venetoclax (U2-V) | 32/165 (19.4%) | 84/165 (50.9%) | 165/165 (100%) |
| Phase 3: Ublituximab + Umbralisib + Venetoclax (U2-V) | 1/56 (1.8%) | 12/56 (21.4%) | 56/56 (100%) |
| Phase 3: Ublituximab + Umbralisib (U2) | 5/56 (8.9%) | 16/53 (30.2%) | 49/53 (92.5%) |
| Event | Phase 2: Ublituximab + Umbralisib + Venetoclax (U2-V) | Phase 3: Ublituximab + Umbralisib + Venetoclax (U2-V) | Phase 3: Ublituximab + Umbralisib (U2) |
|---|---|---|---|
| COVID-19Infections and infestations | 15/165 | 0/56 | 3/53 |
| COVID-19 pneumoniaInfections and infestations | 13/165 | 2/56 | 4/53 |
| PneumoniaInfections and infestations | 9/165 | 2/56 | 2/53 |
| ColitisGastrointestinal disorders | 7/165 | 0/56 | 0/53 |
| Infusion related reactionInjury, poisoning and procedural complications | 2/165 | 1/56 | 2/53 |
| Blood bilirubin increasedInvestigations | 0/165 | 0/56 | 2/53 |
| Febrile neutropeniaBlood and lymphatic system disorders | 5/165 | 2/56 | 0/53 |
| Atrial fibrillationCardiac disorders | 5/165 | 0/56 | 0/53 |
| Acute kidney injuryRenal and urinary disorders | 5/165 | 0/56 | 0/53 |
| PyrexiaGeneral disorders | 3/165 | 1/56 | 1/53 |
| Event | Phase 2: Ublituximab + Umbralisib + Venetoclax (U2-V) | Phase 3: Ublituximab + Umbralisib + Venetoclax (U2-V) | Phase 3: Ublituximab + Umbralisib (U2) |
|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 120/165 | 30/56 | 23/53 |
| Infusion related reactionInjury, poisoning and procedural complications | 112/165 | 38/56 | 26/53 |
| NauseaGastrointestinal disorders | 94/165 | 26/56 | 27/53 |
| Neutrophil count decreasedInvestigations | 77/165 | 20/56 | 10/53 |
| FatigueGeneral disorders | 74/165 | 25/56 | 17/53 |
| Alanine aminotransferase increasedInvestigations | 31/165 | 10/56 | 17/53 |
| InsomniaPsychiatric disorders | 47/165 | 16/56 | 12/53 |
| Aspartate aminotransferase increasedInvestigations | 33/165 | 12/56 | 15/53 |
| HeadacheNervous system disorders | 43/165 | 15/56 | 13/53 |
| DizzinessNervous system disorders | 43/165 | 9/56 | 9/53 |
Safety population consisted of all participants who received at least one dose of any study drug (ublituximab, umbralisib, and venetoclax).
| Age, Continuous(years) | Phase 2: Ublituximab + Umbralisib + Venetoclax (U2-V) | Phase 3: Ublituximab + Umbralisib + Venetoclax (U2-V) | Phase 3: Ublituximab + Umbralisib (U2) | Total |
|---|---|---|---|---|
| Mean | 65.9 (44 to 85) | 65.5 (46 to 91) | 62.9 (38 to 80) | 65.3 (38 to 91) |
| Sex: Female, Male(Participants) | Phase 2: Ublituximab + Umbralisib + Venetoclax (U2-V) | Phase 3: Ublituximab + Umbralisib + Venetoclax (U2-V) | Phase 3: Ublituximab + Umbralisib (U2) | Total |
|---|---|---|---|---|
| Female | 60 | 22 | 14 | 96 |
| Male | 105 | 34 | 39 | 178 |
| Ethnicity (NIH/OMB)(Participants) | Phase 2: Ublituximab + Umbralisib + Venetoclax (U2-V) | Phase 3: Ublituximab + Umbralisib + Venetoclax (U2-V) | Phase 3: Ublituximab + Umbralisib (U2) | Total |
|---|---|---|---|---|
| Hispanic or Latino | 5 | 2 | 1 | 8 |
| Not Hispanic or Latino | 158 | 53 | 49 | 260 |
| Unknown or Not Reported | 2 | 1 | 3 | 6 |
| Race/Ethnicity, Customized(Participants) | Phase 2: Ublituximab + Umbralisib + Venetoclax (U2-V) | Phase 3: Ublituximab + Umbralisib + Venetoclax (U2-V) | Phase 3: Ublituximab + Umbralisib (U2) | Total |
|---|---|---|---|---|
| Race — White/Caucasian | 147 | 51 | 44 | 242 |
| Race — Black or African American | 6 | 2 | 4 | 12 |
| Race — Asian | 2 | 0 | 0 | 2 |
| Race — American Indian or Alaska Native | 1 | 0 | 0 | 1 |
| Race — Hispanic | 1 | 0 | 0 | 1 |
| Race — Unknown | 8 | 3 | 5 | 16 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from May 2019 to primary completion in Dec 2022, 43 months.
Results were first posted in Apr 2024, 1 year 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Ublituximab · Umbralisib
Leukemia, Lymphocytic, Chronic, B-Cell →